Download PDF
Aktuelle Dermatologie 2011; 37(1/02): 47-56
DOI: 10.1055/s-0030-1256016
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Primär kutane B-Zell-Lymphome

Primary Cutaneous B-Cell LymphomasO.  Inhoff1 , E.  Dippel1
  • 1 Hautklinik/Hautttumorzentrum Rheinpfalz, Klinikum der Stadt Ludwigshafen
Further Information

Publication History

Publication Date:
03 February 2011 (online)

Also available at
   Permissions and Reprints

Lernziele

Kenntnisse über primär kutane B-Zell-Lymphome:

Terminologie und Klassifikation Klinik, Histologie und Diagnosestellung Stadieneinteilung Therapie und Prognose

Literatur

  • 1 Willemze R, Jaffe E S, Burg G et al. WHO-EORTC classification for cutaneous lymphomas.  Blood. 2005;  105 3768-3785
    CrossrefPubMedGoogle Scholar
  • 2 Assaf C, Gellrich S, Steinhoff M et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).  J Dtsch Dermatol Ges. 2007;  5 662-668
    PubMedGoogle Scholar
  • 3 Dummer R, Stadler R, Sterry W. Cutaneous lymphomas.  J Dtsch Dermatol Ges. 2007;  5 605-617
    PubMedGoogle Scholar
  • 4 Senff N J, Noordijk E M, Kim Y H European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma et al.. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.  Blood. 2008;  112 1600-1609
    CrossrefPubMedGoogle Scholar
  • 5 Burg G, Kempf W, Cozzio A et al. Cutaneous malignant lymphomas: update 2006.  J Dtsch Dermatol Ges. 2006;  4 914-933
    PubMedGoogle Scholar
  • 6 Fink-Puches R, Zenahlik P, Bäck B et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients.  Blood. 2002;  99 800-805
    CrossrefPubMedGoogle Scholar
  • 7 Child F J, Woollons A, Price M L et al. Multiple cutaneous immunocytoma with secondary anetoderma: a report of two cases.  Br J Dermatol. 2000;  143 165-170
    CrossrefPubMedGoogle Scholar
  • 8 de Leval L, Harris N L, Longtine J et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification.  Am J Surg Pathol. 2001;  25 732-741
    CrossrefPubMedGoogle Scholar
  • 9 Swerdlow S H, Campo E, Harris N L et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues.. Lyon: IARC Press; 2008
    Google Scholar
  • 10 Grange F, Petrella T, Beylot-Barry M et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.  Blood. 2004;  103 3662-3668
    CrossrefPubMedGoogle Scholar
  • 11 Hallermann C, Niermann C, Fischer R J et al. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.  J Am Acad Dermatol. 2007;  56 588-597
    CrossrefPubMedGoogle Scholar
  • 12 Ponzoni M, Ferreri A J, Campo E et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.  J Clin Oncol. 2007;  25 3168-3173
    CrossrefPubMedGoogle Scholar
  • 13 Koens L, Vermeer M H, Willemze R et al. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma.  Am J Surg Pathol. 2010;  34 1043-1048
    CrossrefPubMedGoogle Scholar
  • 14 Kim Y H, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).  Blood. 2007;  110 479-484
    CrossrefPubMedGoogle Scholar
  • 15 Cronin C G, Swords R, Truong M T et al. Clinical utility of PET/CT in lymphoma.  Am J Roentgenol. 2010;  194 W91-W103
    CrossrefPubMedGoogle Scholar
  • 16 Senff N J, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.  Br J Dermatol. 2007;  157 1205-1211
    CrossrefPubMedGoogle Scholar
  • 17 Stadler R, Assaf C, Klemke C D et al. Short German guidelines: cutaneous lymphomas.  J Dtsch Dermatol Ges. 2008;  6 (Suppl. 1) S25-S31
    PubMedGoogle Scholar
  • 18 Cerroni L, Zöchling N, Pütz B et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma.  J Cutan Pathol. 1997;  24 457-461
    CrossrefPubMedGoogle Scholar
  • 19 Goodlad J R, Davidson M M, Hollowood K et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland.  Am J Surg Pathol. 2000;  24 1279-1285
    CrossrefPubMedGoogle Scholar
  • 20 Li C, Inagaki H, Kuo T T et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases.  Am J Surg Pathol. 2003;  27 1061-1069
    CrossrefPubMedGoogle Scholar
  • 21 Wood G S, Kamath N V, Guitart J et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States.  J Cutan Pathol. 2001;  28 502-507
    CrossrefPubMedGoogle Scholar
  • 22 Senff N J, Hoefnagel J J, Jansen P M et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers.  J Clin Oncol. 2007;  25 1581-1587
    CrossrefPubMedGoogle Scholar
  • 23 Kodama K, Massone C, Chott A et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients.  Blood. 2005;  106 2491-2497
    CrossrefPubMedGoogle Scholar
  • 24 Fink-Puches R, Wolf I H, Zalaudek I et al. Treatment of primary cutaneous B-cell lymphoma with rituximab.  J Am Acad Dermatol. 2005;  52 847-853
    CrossrefPubMedGoogle Scholar
  • 25 Mian M, Marcheselli L, Luminari S et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11).  Ann Hematol. [in press]
    PubMedGoogle Scholar
  • 26 Pulini S, Rupoli S, Goteri G et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.  Eur J Haematol. 2009;  82 184-193
    CrossrefPubMedGoogle Scholar
  • 27 Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).  Blood. 2003;  101 4279-4284
    CrossrefPubMedGoogle Scholar
  • 28 Skvortsova I, Skvortsov S, Popper B A et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via caspase-dependent and – independent mechanisms.  J Radiat Res. (Tokyo) 2006;  47 183-196
    CrossrefPubMedGoogle Scholar
  • 29 Skvortsova I, Popper B A, Skvortsov S et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin’s lymphoma cells.  J Radiat Res. (Tokyo) 2005;  46 241-248
    CrossrefPubMedGoogle Scholar

Dr. med. Oliver Inhoff

Funktionsoberarzt
Hautklinik/Hauttumorzentrum Rheinpfalz
Klinikum Ludwigshafen

Bremserstr. 79
67063 Ludwigshafen

Email: inhoffo@klilu.de

      >